RESUMO
Background: The reduction in long-term mortality after acute myocardial infarction (AMI) is less pronounced than that of in-hospital mortality among patients with AMI complicated by heart failure (HF) and/or in those with a high residual thrombotic risk (HTR). Aim: To investigate the relative prognostic significance of HTR and HF in AMI survivors. Methods: This retrospective cohort study enrolled patients admitted for AMI in 2014-2015 in all Italian hospitals. HTR was defined as at least one of the following conditions: previous AMI, ischemic stroke or other vascular disease, type 2 diabetes, renal failure. Patients were classified into four categories: uncomplicated AMI; AMI with HTR; AMI with HF and AMI with both HTR and HF (HTR + HF). Cox proportional hazard model was used to evaluate the impact of HTR, HF and HTR + HF on the 5-year prognosis. A time-varying coefficient analysis was performed to estimate the 5-year trend of HR for major averse cardiac and cerebrovascular events (MACCE). Results: a total of 174.869 AMI events were identified. The adjusted 5-year HR for MACCE was 1.74 (p < 0.0001) and 1.75 (p < 0.0001) in HTR and HF patients vs uncomplicated patients, respectively. The coexistence of HTR and HF furtherly increased the risk of MACCE (HR = 2.43, p < 0.0001) over the first 3 years after AMI. Conclusion: Either HRT and HF confer an increased 5-year hazard of MACCE after AMI. The coexistence of HTR and HF doubled the overall 5-year risk of MACCE after AMI.
RESUMO
BACKGROUND: Coronary artery disease (CAD) is a common underlying cause of de novo heart failure (HF) and is associated with poor outcome despite advances in medical therapy. There are no data clearly supporting coronary angiogram (CVG) and revascularization in this setting. METHODS: We analysed a nationwide, comprehensive, and universal administrative database of consecutive patients for the first time admitted in hospital for HF, without a history of CAD, who survived 30 days after index admission from 2015 to 2019 in Italy. Enrolled patients were classified into subjects who did not undergo CVG; those who underwent CVG without coronary revascularization; those who underwent percutaneous coronary intervention (PCI); and those who underwent coronary artery bypass grafting (CABG). RESULTS: During the study period, 342,090 patients were hospitalized for the first time due to HF and survived 30 days after admission, in Italy. Among them, 30,806 (9.0%) patients underwent CVG without undergoing coronary revascularization, 5855 (1.7%) underwent PCI and 1594 (0.5%) underwent CABG. After adjusting for age, gender and comorbidity, the hazard ratio (HR) for 1-year all-cause mortality in patients undergoing CVG vs no CVG were 0.56 (p < 0.0001), 0.66 (p < 0.0001) and 0.83 (p = 0.020) for CVG, PCI and CABG patients, respectively. When considering the re-hospitalization for HF as the outcome, using death as a competing risk, after multiple corrections, CVG (HR = 0.80; p < 0.0001) and CABG (HR = 0.73; p < 0.0002) were protective versus No CVG, but not PCI (HR = 1.02; p = 0.642). CONCLUSIONS: This study provides evidence that CVG and coronary revascularization may be beneficial for patients with de novo HF.
RESUMO
OBJECTIVES: Gender difference in the outcome after type A aortic dissection (TAAD) surgery remains an issue of ongoing debate. In this study, we aimed to evaluate the impact of gender on the short- and long-term outcome after surgery for TAAD. METHODS: A multicentre European registry retrospectively included all consecutive TAAD surgery patients between 2005 and 2021 from 18 hospitals across 8 European countries. Early and late mortality, and cumulative incidence of aortic reoperation were compared between genders. RESULTS: A total of 3902 patients underwent TAAD surgery, with 1185 (30.4%) being females. After propensity score matching, 766 pairs of males and females were compared. No statistical differences were detected in the early postoperative outcome between genders. Ten-year survival was comparable between genders (47.8% vs 47.1%; log-rank test, P = 0.679), as well as cumulative incidences of distal or proximal aortic reoperations. Ten-year relative survival compared to country-, year-, age- and sex-matched general population was higher among males (0.65) compared to females (0.58). The time-period subanalysis revealed advancements in surgical techniques in both genders over the years. However, an increase in stroke was observed over time for both populations, particularly among females. CONCLUSIONS: The past 16 years have witnessed marked advancements in surgical techniques for TAAD in both males and females, achieving comparable early and late mortality rates. Despite these findings, late relative survival was still in favour of males.
Assuntos
Dissecção Aórtica , Sistema de Registros , Humanos , Masculino , Feminino , Dissecção Aórtica/cirurgia , Dissecção Aórtica/mortalidade , Estudos Retrospectivos , Europa (Continente)/epidemiologia , Pessoa de Meia-Idade , Idoso , Fatores Sexuais , Resultado do Tratamento , Reoperação/estatística & dados numéricos , Aneurisma da Aorta Torácica/cirurgia , Aneurisma da Aorta Torácica/mortalidade , Complicações Pós-Operatórias/epidemiologia , Pontuação de PropensãoRESUMO
Atherosclerosis is a systemic disease that can involve different arterial districts. Traditionally, the focus of cardiologists has been on the diagnosis and treatment of atherosclerotic coronary artery disease (CAD). However, atherosclerosis localization in other districts is increasingly common and is associated with an increased risk of CAD and, more generally, of adverse cardiovascular events. Although the term peripheral arterial disease (PAD) commonly refers to the localization of atherosclerotic disease in the arterial districts of the lower limbs, in this document, in accordance with the European Society of Cardiology guidelines, the term PAD will be used for all the locations of atherosclerotic disease excluding coronary and aortic ones. The aim of this review is to report updated data on PAD epidemiology, with particular attention to the prevalence and its prognostic impact on patients with CAD. Furthermore, the key points for an appropriate diagnostic framework and a correct pharmacological therapeutic approach are summarized, while surgical/interventional treatment goes beyond the scope of this review.
Assuntos
Aterosclerose , Doença da Artéria Coronariana , Doença Arterial Periférica , Humanos , Aterosclerose/complicações , Aterosclerose/diagnóstico , Aterosclerose/epidemiologia , Doença da Artéria Coronariana/diagnóstico , Doença da Artéria Coronariana/epidemiologia , Doença da Artéria Coronariana/terapia , Doença Arterial Periférica/diagnóstico , Doença Arterial Periférica/epidemiologia , Doença Arterial Periférica/terapia , Coração , AortaRESUMO
BACKGROUND: Bleeding is one of the most frequent complications in patients undergoing transcatheter aortic valve replacement (TAVR). Importantly, major bleeding is associated with poor clinical outcomes after TAVR. However, large studies on bleeding complications in the contemporary TAVR population are limited. OBJECTIVES: The aim of this study was to assess the incidence, temporal trends, clinical outcomes, and predictors of bleeding in patients undergoing transfemoral TAVR. METHODS: The CENTER2 study is a pooled patient-level database from 10 clinical studies including patients who underwent TAVR between 2007 and 2022. RESULTS: A total of 23,562 patients underwent transfemoral TAVR. The mean age was 81.5 ± 6.7 years, and 56% were women. Major bleeding within the first 30 days was observed in 1,545 patients (6.6%). Minor bleeding was reported in 1,143 patients (4.7%). Rates of major bleeding decreased from 11.5% in 2007-2010 to 5.5% in 2019-2022 (Ptrend < 0.001). Dual antiplatelet therapy was associated with higher major bleeding rates compared with single antiplatelet therapy (12.2% vs 9.1%; OR: 1.40; 95% CI: 1.13-1.72; P = 0.002). Patients with major bleeding had increased mortality risk during the first 30 days (14.1% vs 4.3%; OR: 3.66; 95% CI: 3.11-4.31; P < 0.001) and during 1-year follow-up (27.8% vs 14.5%; HR: 1.50; 95% CI: 1.41-1.59; P < 0.001). Minor bleeding did not affect 1-year mortality risk (16.7% vs 14.5%; HR: 1.11; 95% CI: 0.93-1.32; P = 0.27). Predictors of major bleeding were female sex and peripheral vascular disease. CONCLUSIONS: Bleeding complications remain frequent and important in patients undergoing transfemoral TAVR. Increased mortality risk in major bleeding persists after the initial 30 days. (Cerebrovascular Events in Patients Undergoing Transcatheter Aortic Valve Implantation With Balloon-Expandable Valves Versus Self-Expandable Valves [CENTER]; NCT03588247).
Assuntos
Estenose da Valva Aórtica , Substituição da Valva Aórtica Transcateter , Humanos , Feminino , Idoso , Idoso de 80 Anos ou mais , Masculino , Substituição da Valva Aórtica Transcateter/efeitos adversos , Valva Aórtica/diagnóstico por imagem , Valva Aórtica/cirurgia , Incidência , Estenose da Valva Aórtica/diagnóstico por imagem , Estenose da Valva Aórtica/cirurgia , Resultado do Tratamento , Hemorragia/epidemiologia , Hemorragia/etiologia , Fatores de RiscoRESUMO
Background: Surgery for type A aortic dissection (TAAD) is associated with high risk of mortality. Current risk scoring methods have a limited predictive accuracy. Methods: Subjects were patients who underwent surgery for acute TAAD at 18 European centers of cardiac surgery from the European Registry of Type A Aortic Dissection (ERTAAD). Results: Out of 3,902 patients included in the ERTAAD, 2,477 fulfilled the inclusion criteria. In the validation dataset (2,229 patients), the rate of in-hospital mortality was 18.4%. The rate of composite outcome (in-hospital death, stroke/global ischemia, dialysis, and/or acute heart failure) was 41.2%, and 10-year mortality rate was 47.0%. Logistic regression identified the following patient-related variables associated with an increased risk of in-hospital mortality [area under the curve (AUC), 0.755, 95% confidence interval (CI), 0.729-0.780; Brier score 0.128]: age; estimated glomerular filtration rate; arterial lactate; iatrogenic dissection; left ventricular ejection fraction ≤50%; invasive mechanical ventilation; cardiopulmonary resuscitation immediately before surgery; and cerebral, mesenteric, and peripheral malperfusion. The estimated risk score was associated with an increased risk of composite outcome (AUC, 0.689, 95% CI, 0.667-0.711) and of late mortality [hazard ratio (HR), 1.035, 95% CI, 1.031-1.038; Harrell's C 0.702; Somer's D 0.403]. In the validation dataset (248 patients), the in-hospital mortality rate was 16.1%, the composite outcome rate was 41.5%, and the 10-year mortality rate was 49.1%. The estimated risk score was predictive of in-hospital mortality (AUC, 0.703, 95% CI, 0.613-0.793; Brier score 0.121; slope 0.905) and of composite outcome (AUC, 0.682, 95% CI, 0.614-0.749). The estimated risk score was predictive of late mortality (HR, 1.035, 95% CI, 1.031-1.038; Harrell's C 0.702; Somer's D 0.403), also when hospital deaths were excluded from the analysis (HR, 1.024, 95% CI, 1.018-1.031; Harrell's C 0.630; Somer's D 0.261). Conclusions: The present analysis identified several baseline clinical risk factors, along with preoperative estimated glomerular filtration rate and arterial lactate, which are predictive of in-hospital mortality and major postoperative adverse events after surgical repair of acute TAAD. These risk factors may be valuable components for risk adjustment in the evaluation of surgical and anesthesiological strategies aiming to improve the results of surgery for TAAD. Clinical Trial Registration: https://clinicaltrials.gov, identifier NCT04831073.
RESUMO
BACKGROUND Bioprosthetic valves are increasingly implanted in patients with aortic valve stenosis. These valves have a limited durability. Valve-in-valve (ViV) transcatheter aortic valve implanta tion (TAVI) is a treatment option for bioprosthetic valve failure. Both balloon-expandable (BE) and self-expandable (SE) valves are widely used in ViV-TAVI procedures. However, studies comparing outcomes between these fundamentally different valve designs in ViV-TAVI are lacking. METHODS The CENTER study is a patient pooled analysis, comprising data of 12,381 patients undergoing transfemoral TAVI in 6 countries. We assessed differences in clinical outcomes between SE and BE valves in ViV-TAVI patients, as defined by the Valve Academic Research Consortium. RESULTS A total of 256 patients were treated with transfemoral ViV TAVI. Of these, 50% were female, median age was 82 (IQR: 78-85) years, and median STS-PROM was 6.3% (IQR: 4.0%-10.4%). SE valves were used in 162 patients (63%) and BE valves in 94 (37%) patients. SE and BE valve recipients were similar regarding female sex (53% vs 47%; P » 0.38), age (82 years [78-85] vs 81 [78-84]; P » 0.24), and STS PROM (6.5% [4.2%-10.2%] vs 6.2% [4.0%-10.9%]; P » 1.00). Third generation valves were used in 91 (56%) of SE valves and in 40 (43%) of BE valves. There was a trend towards lower 30-day mortality in SE valve patients (3% vs 7%; RR: 0.37; 95% CI: 0.11-1.26; P » 0.10). In addition, 30-day major bleeding was less frequent in SE valve patients (3% vs 13%; RR: 0.27; 95% CI: 0.09-0.79; P » 0.01). Rates of conversion to surgery (1% vs 0; P » 0.44) and device success were similar (90% vs 92%; P » 0.62). Moreover, 30-day rates of stroke (1.9% vs 4.6%; P » 0.22), myocardial infarction (0.7% vs 1.8%; P » 0.46), and permanent pacemaker implantation (9.3% vs 7.9%; P » 0.70) were similar. There was no difference in 1-year mortality (12.5% vs 17.6%; P » 0.32) and stroke rates (3.7% vs 7.4%; P » 0.25). CONCLUSION There was a trend toward lower 30-day mortality in ViV-TAVI patients treated with SE valves. Moreover, the use of SE valves in ViV-TAVI was associated with lower rates of major bleeding than BE valves. Our findings warrant randomized controlled trials directly comparing SE and BE valves in ViV-TAVI patients.
Assuntos
Angioplastia Coronária com Balão , Substituição da Valva Aórtica TranscateterRESUMO
BACKGROUND Atrial fibrillation (AF) is common in patients with aortic valve stenosis undergoing transcatheter aortic valve implanta tion (TAVI). We compared clinical outcomes between TAVI patients with baseline AF versus TAVI patients without AF. METHODS The CENTER study is an international collaboration including 12,381 patients treated with transfemoral TAVI. This pooled analysis consists of patient level data from 10 different studies. End points were stroke and mortality rates at 30 days and 1 year after TAVI as defined by the Valve Academic Research Consortium. RESULTS Of the 12,381 patients, 58% were female, the mean age was 81.5 7.0 years, and the median logistic EuroSCORE was 14.4% (9.0%- 23.0%). A total of 3,354 patients (27%) had known baseline AF. In patients with AF, there was a trend toward higher in-hospital mor tality (5.3% vs 3.5%; relative risk [RR]: 1.18; 95% confidence interval [CI]: 0.99-1.41; P » 0.06). Moreover, 30-day mortality (7.1% vs 5.3%; RR: 1.35; 95% CI: 1.16-1.59; P < 0.001) as well as 1-year mortality (20.8% vs 15.3%; RR: 1.35; 95% CI: 1.23-1.52; P < 0.001) was higher in AF patients. In contrast, stroke rates were comparable in patients with versus without AF during hospital admission (2.2% vs 2.0%, P » 0.60), at 30 days (2.9% vs 2.4%, P » 0.18), and 1 year after TAVI (5.3% vs 5.1%, P » 0.75). Also, 30-day rates of myocardial infarction (0.8% vs 1.0%, P » 0.38) and major bleeding (7.6% vs 7.3%, P » 0.53) were similar between both patient groups. However, permanent pace makers were more frequently implanted in AF patients (14.8% vs 13.4%; RR: 1.11; 95% CI: 1.00-1.23; P » 0.05). CONCLUSION In this global study of >12,000 patients undergoing transfemoral TAVI, AF was associated with higher 30-day and 1-year mortality. Moreover, patients with AF more frequently required a permanent pacemaker. Although AF is a common condition in pa tients undergoing TAVI, it is undoubtedly not a benign arrhythmia. Therefore, our results underscore the evident need for further research in treatment options for patients with AF undergoing TAVI.
Assuntos
Fibrilação Atrial , Substituição da Valva Aórtica TranscateterRESUMO
AIMS: The aim of this study was to compare clinical outcomes of patients undergoing transfemoral transcatheter aortic valve implantation (TAVI) with balloon-expandable (BE) valves vs. self-expandable (SE) valves. Transcatheter aortic valve implantation is a minimally invasive and lifesaving treatment in patients with aortic valve stenosis. Even though BE-valves and SE-valves are both commonly used on a large scale, adequately sized trials comparing clinical outcomes in patients with severe aortic valve stenosis treated with BE-valves compared with SE-valves are lacking. METHODS AND RESULTS: In this CENTER-collaboration, data from 10 registries or clinical trials, selected through a systematic search, were pooled and analyzed. Propensity score methodology was used to reduce treatment selection bias and potential confounding. The primary endpoints were mortality and stroke at 30 days follow-up in patients treated with BE-valves compared with SE-valves. Secondary endpoints included clinical outcomes, e.g. bleeding during hospital admission. All outcomes were split for early-generation BE-valves compared with early-generation SE-valves and new-generation BE-valves with new-generation SE-valves. The overall patient population (N = 12 381) included 6239 patients undergoing TAVI with BE-valves and 6142 patients with SE-valves. The propensity matched population had a mean age of 81 ± 7 years and a median STS-PROM score or 6.5% [interquartile range (IQR) 4.0-13.0%]. At 30-day follow-up, the mortality rate was not statistically different in patients undergoing TAVI with BE-valves compared with SE-valves [BE: 5.3% vs. SE: 6.2%, relative risk (RR) 0.9; 95% confidence interval (CI) 0.7-1.0, P = 0.10]. Stroke occurred less frequently in patients treated with BE-valves (BE: 1.9% vs. SE: 2.6%, RR 0.7; 95% CI 0.5-1.0, P = 0.03). Also, patients treated with BE-valves had a three-fold lower risk of requiring pacemaker implantation (BE: 7.8% vs. SE: 20.3%, RR 0.4; 95% CI 0.3-0.4, P < 0.001). In contrast, patients treated with new-generation BE-valves more frequently experienced major and life-threatening bleedings compared with new-generation SE-valves (BE: 4.8% vs. SE: 2.1%, RR 2.3; 95% CI 1.6-3.3, P < 0.001). CONCLUSION: In this study, which is the largest study to compare valve types in TAVI, we demonstrated that the incidence of stroke and pacemaker implantation was lower in patients undergoing transfemoral TAVI with BE-valves compared with SE-valves. In contrast, patients treated with new-generation BE-valves more often suffered from major or life-threatening bleedings than patients with new-generation SE-valves. Mortality at 30-days was not statistically different in patients treated with BE-valves compared with SE-valves. This study was a propensity-matched analysis generated from observational data, accordingly current outcomes will have to be confirmed in a large scale randomized controlled trial. (AU)